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INTRODUCTION
The disease burden from respiratory infection is greater
than that of any other cause of disease (232). In 2002, 18% of
mortality for children younger than 5 years of age was caused
by respiratory infections; diarrheal disease (15%) and malaria
(11%) were the next greatest causes (352). Respiratory infec-
tions account not only for increased mortality but also for
increased morbidity in this age group: between 22% (United
Kingdom [242]) and 26.7% (Belgium [222]) of all hospitaliza-
tions and between 33.5% (Italy [287]) and 59% (United King-
dom [247]) of general practitioner consultations are due to
respiratory viral infection. These respiratory infections occur
with increased frequency in early life compared to adulthood
(234), with approximately 5 to 6 infections per year (58).
Respiratory tract infections in the young also impose a large
and intermittent burden on the health care infrastructure. For
community-based care, the mean cost per acute respiratory
infection (ARI) has been estimated to be between US$140 (86)
and US$240 (184), with the cost depending in part on the
infecting agent. (For comparison purposes, costs have been
converted from original data into U.S. dollars using the values
US$1  AUD$1.3  €0.75  £0.5 [summer 2008].) These
estimated costs include direct and indirect costs (e.g., loss of
earnings of the caregivers). Hospitalization costs are estimated
at an average of US$5,250 per case of respiratory syncytial
virus (RSV) bronchiolitis (33, 86, 311). The total annual cost of
respiratory infection of young children in Germany was esti-
mated to be US$213 million (86).
FROM THE BEDSIDE: SYMPTOMS, SIGNS,
AND TREATMENT
Upper Respiratory Tract Infection
Most respiratory virus infections in early childhood are con-
fined to the upper respiratory tract, leading to symptoms of the
common cold, with coryza, cough, and hoarseness. Upon ex-
amination, rhinitis and pharyngitis are found and are fre-
* Corresponding author. Mailing address: Department of Cellular
and Molecular Medicine, St. George’s University of London, Cranmer
Terrace, London SW17 0RE, United Kingdom. Phone: 44 20 8725
5349. Fax: 44 20 8725 3487. E-mail: jtregoning@sgul.ac.uk.
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quently associated with some conjunctival and tympanic vas-
cular injections. In some cases, symptoms and signs of otitis
media occur, such as earache, tenderness of the tragus upon
pressure, and a red bulging tympanic membrane upon inspec-
tion. Upper respiratory tract infection (URTI) in infants is
often accompanied by fever and may lead to lethargy and poor
feeding. Specific treatment is usually neither available nor re-
quired. However, analgesics/antipyretics (e.g., paracetamol)
and, in some cases, nasal decongestants may be helpful in
reducing discomfort and symptoms, making feeding easier, and
allowing an adequate supply of oral fluids.
Lower Respiratory Tract Infection
About one-third of infants with respiratory viral infections
develop lower respiratory tract symptoms such as tachypnea,
wheeze, severe cough, breathlessness, and respiratory distress.
These symptoms may be accompanied by clinical signs includ-
ing nasal flaring; jugular, intercostal, and thoracic indrawings;
rarely cyanosis; and, on auscultation of the chest wheeze,
crackles, crepitations, and inspiratory rhonchi or generally re-
duced breath sounds due to air trapping and peripheral hyper-
inflation of the lung. In RSV infection, recurrent episodes of
apnea are a threat to infants less than 6 months of age.
Some clinicians make distinctions between bronchitis, bron-
chiolitis, and pneumonia to describe predominantly proximal
(large)-airway disease, small (conducting)-airway disease, or
involvement of the alveolar compartment. However, the lack
of internationally agreed-upon definitions makes the use of
these pathological descriptions as clinical diagnoses conten-
tious and, since the treatment is the same regardless of these
distinctions, probably irrelevant.
The treatment and care for viral lower respiratory tract
infection (LRTI) depend on the assessment of the severity of
respiratory compromise by using measurements of O2 satura-
tion and of blood gases and the clinical assessment of the
severity of respiratory distress and of respiratory exhaustion
with decreased respiratory effort, increasing CO2 retention,
and respiratory acidosis. In addition, the consequences of re-
spiratory compromise, in particular the inability to feed and
drink, determine the management of these infants. Additional
risk factors and preexisting illness (e.g., chronic lung disease of
prematurity or history of reactive-airway disease) also influ-
ence disease management.
Extrapulmonary manifestations of LRTI, which have been
described for RSV infection, are observed rarely. They include
seizures, hyponatremia, cardiac arrhythmias, cardiac failure,
and hepatitis (87). Interestingly, viral RNA not only has been
detected in the respiratory tract, where the epithelium is the
primary site of infection and viral replication, but also is tran-
siently present in peripheral blood mononuclear cells and, per-
haps very rarely, in cerebrospinal fluid and cardiac muscle,
raising the possibility of occasional extrapulmonary spread
(87).
Viral Diagnosis of Infant LRTI
For infants with LRTI treated as outpatients, a virological
diagnosis is often not sought. This is justifiable for healthy
infants, since the virological diagnosis does not predict the
severity or length of disease, nor does it usually lead to specific
therapy. Most respiratory viruses can cause LRTI of various
severities and with a wide range of manifestations, and for
most respiratory viruses, clinically useful antiviral agents do
not exist. However, the detection of a viral cause of LRTI can
be useful since it reduces the use of antibiotics, which is un-
warranted in most cases of viral LRTI. For infants at risk of
severe LRTI (e.g., prematurity and congenital heart disease),
an early viral diagnosis is useful. RSV infection of these infants
often leads to severe LRTI, requiring close monitoring of dis-
ease and, in the case of deterioration, early hospitalization.
For 1 to 2% of infants, LRTI requires hospitalization (120).
In these cases, a viral diagnosis should be sought upon presen-
tation by antigen detection assays or PCR to inform decisions
on the cohorting of patients and to prevent nosocomial infec-
tions.
Antiviral Drugs Currently in Use
For influenza A and B viruses, the neuraminidase inhibitors
oseltamivir and zanamivir are licensed as antiviral drugs but
only for patients between the ages of 1 and 5 years, respec-
tively, and not for infants. These drugs can be used for pos-
texposure prophylaxis and the treatment of influenza virus
(IV) if they can be given within 48 h after exposure or 36 h
after first symptoms. Neuraminidase inhibitors are recom-
mended only for children with chronic morbidity who are at an
increased risk of severe influenza-induced disease. Treatment
shortens symptoms by about 1 day and may reduce disease
severity (297). Neuraminidase inhibitors are not helpful for
established influenza infection and do not improve severe
LRTI. In a recent update, rimantadine and amantadine were
no longer recommended by the National Institute for Clinical
Excellence (NICE) for the treatment of influenza. However,
with the emergence of H1N1 influenza A virus strains that are
resistant to oseltamivir, combination treatments of oseltamivir
and rimantadine or amantadine are currently (as of August
2009) recommended by the U.S. Centers for Disease Control
and Prevention.
Ribavirin is an antiviral drug that is very effective against
RSV in vitro and is licensed for use by inhalation for severe
RSV bronchiolitis. However, due to teratogenic side effects,
ribavirin cannot be administered as an aerosol in the presence
of pregnant women (e.g., medical staff). In addition, regarding
clinical use, ribavirin has generally been thought to be disap-
pointing and to provide little or no benefit, possibly because
once developed, the severe inflammation in RSV bronchiolitis
may be maintained independently of the presence of live RSV
virions. However, a recent study reported decreases in post-
bronchiolitic asthma and recurrent wheeze in 6-year-old chil-
dren who were treated with ribavirin during RSV bronchiolitis
(53). A Cochrane review found that published reports of trials
of ribavirin lack the power to provide reliable estimates of its
effects but suggested that ribavirin may reduce the duration of
mechanical ventilation and hospitalization (341).
The anti-RSV antibody palivizumab, although not techni-
cally an antiviral drug, reduces the number of RSV cases
requiring hospitalization for at-risk infants by 55% if given
prophylactically (142a). In the original study, premature
infants of 35 weeks of gestation with and without bron-
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chopulmonary dysplasia were treated with palivizumab dur-
ing their first winter season, resulting in 39% and 78%
reductions in RSV-associated hospitalizations, respectively.
Other high-risk groups for severe RSV LRTI for whom
RSV immunoprophylaxis is recommended by the American
Academy of Pediatrics include children under 2 years of age
with chronic lung disease or with congenital heart disease
(e.g., congestive heart failure, pulmonary hypertension, and
cyanotic heart disease). Importantly, palivizumab does not
have beneficial effects on established RSV bronchiolitis in
immunocompetent infants and is therefore used for treat-
ment only on an individual basis for immunocompromised
patients. A new anti-RSV antibody derived from palivi-
zumab with enhanced anti-RSV neutralizing activity, mota-
vizumab, is currently being evaluated in clinical trials (275).
Other antiviral drugs are in development for RSV and rhi-
novirus (RV) and are described below.
Bronchodilators, Corticosteroids, Antibiotics, and
Other Treatments
In the absence of effective antivirals for severe infant LRTI,
medical treatment is focused on drugs designed to overcome
airway obstruction and the resulting respiratory distress. In
analogy to asthma treatment, bronchodilators have been used
widely, including 2 agonists, nebulized epinephrine, and an-
timuscarinics such as ipatropium bromide. However, in gen-
eral, results of these interventions have been disappointing.
Studies assessing the effects of these bronchodilators on lung
function and clinical outcome yielded conflicting results. A
recent Cochrane review concluded that bronchodilator treat-
ment can improve clinical symptom scores in the short term in
viral LRTI cases but that it does not reduce the duration of
hospitalization and increases treatment cost (104). Studies
published since the Cochrane review was performed support
the argument that bronchodilators have no benefit for infant
bronchiolitis (159, 193, 292). In line with this finding, the
American Academy of Pediatrics recommends that inhaled
bronchodilators should not be used routinely for the manage-
ment of bronchiolitis (317). One possible exception is for LRTI
with underlying reactive-airway disease and where wheeze is
the hallmark symptom of LRTI, where short-acting 2 agonists
may be effective for individual patients. However, short-acting
2 agonists need to be used cautiously in infants due to the risk
of paradoxical 2 agonist reactions (38).
Another widely used approach was (and often still is) the use
of corticosteroids in order to control airway inflammation and
subsequent respiratory symptoms. Again, a multitude of stud-
ies using low-dose and high-dose inhaled corticosteroids as
well as systemic application yielded conflicting results. The
majority of those studies failed to demonstrate relevant reduc-
tions in LRTI symptoms, length of hospital stay, or need for
mechanical ventilation. A meta-analysis of studies comparing
systemic glucocorticoid treatment to placebo did not find any
difference in the length of hospital stay or clinical score for
infants and young children with LRTI from either group (252).
The effect may vary according to the infecting virus. There is
little supporting evidence for the benefit of glucocorticoids for
RSV bronchiolitis (40, 68) or the delayed effects of RSV bron-
chiolitis (93), although a recent study showed a possible partial
effect of combined treatment with a bronchodilator and a glu-
cocorticoid (262). One possible suggestion for their failure to
relieve symptoms is that glucocorticoid administration in cases
of RSV does not reduce cytokine production (307). There is
limited information about glucocorticoids and influenza in
infants, but for H5N1 infection of adults, there appeared to
be no beneficial effect (128), and the data for severe acute
respiratory syndrome (SARS) are inconclusive (316). How-
ever, glucocorticoids may have an effect on rhinovirus-in-
duced recurrent wheezing (152, 191). Glucocorticoids may
also be beneficial for the treatment of croup (17, 30), and
croup is most often associated with parainfluenza virus
(PIV), although the viral etiology was not demonstrated in
those studies. Based on this evidence, the routine use of
inhaled or systemic corticosteroids is not recommended for
cases of RSV LRTI by most guidelines but may be of more
use for defined cases of croup or RV infection.
The same idea holds for antibiotics. A recent Cochrane
review found only one study comparing ampicillin to placebo
that met the inclusion criteria. That study did not show any
difference between the groups regarding the duration of illness
or the number of deaths from LRTI (310). There has recently
been particular interest in macrolide antibiotics, which are
effective against atypical bacteria and which are also thought to
have direct anti-inflammatory properties. A recent study of
clarithromycin (320), which has been heavily criticized for in-
herent methodological defects (167, 171), reported a statisti-
cally significant reduction in the length of hospital stay and the
need for supplemental oxygen and 2 agonist treatment. In
contrast, a recent multicenter, randomized, double-blind, pla-
cebo-controlled trial of azithromycin for treatment of RSV
LRTI failed to show any difference in the duration of hos-
pitalization, oxygen supplementation, or nasal/gastric tube
feeding or in RSV symptom scores (168). These data suggest
that infants and young children with viral LRTI do not
benefit from routine treatment with antibiotics. Other ther-
apeutic approaches that have also failed to provide benefit
to small children with viral LRTI include inhaled furo-
semide (20), recombinant DNase (32), or helium/oxygen
inhalation (199) treatment.
Supportive Treatment and Inhalation of Hypertonic Saline
Given the lack of effective medications, current treatment
for severe viral LRTI in infants relies on supportive mea-
sures only. These measures include supplementation of ox-
ygen, monitoring of apnea, nasal/gastric tube feeding or intra-
venous fluids, and, if required, respiratory support with nasal
bi-level positive-airway pressure (BiPAP) or intubation and
mechanical ventilation. For infants with LRTI requiring me-
chanical ventilation, surfactant has been used. A Cochrane
meta-analysis that included 3 studies that showed some reduc-
tion in the duration of mechanical ventilation and in the length
of stay in intensive care concluded that there are no sufficiently
powered data to provide reliable estimates of surfactant effects
on ventilated infants with LRTI (340).
A promising new development is the use of hypertonic saline
inhalation. A recent trial of this treatment, which has been
successfully used for patients with cystic fibrosis, reported a
reduction of 26% in the length of hospitalization for infants
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with acute viral bronchiolitis (182, 361). Provided that larger
studies that focus on children under 6 months of age and
exclude noneffective therapies confirm the beneficial effect of
hypertonic saline inhalation, this treatment could become a
new useful tool for the management of viral LRTI.
TO THE BENCH: EPIDEMIOLOGY AND GENETICS
Viral Diagnosis and Etiology
Comparison of the viral causes of infection provides a useful
starting point for an understanding of illness following respi-
ratory infection. It also provides data relevant for the devel-
opment of prevention strategies. The following viruses (in no
particular order) have been detected during acute respiratory
infections (ARIs): adenovirus (AV), coronavirus (CoV), en-
terovirus (EV), human metapneumovirus (hMPV), influenza
virus (IV), parainfluenza virus (PIV), rhinovirus (RV), and
respiratory syncytial virus (RSV). There are also more recently
identified viruses including bocavirus (BoV) and polyomavi-
ruses.
There are four principal ways in which respiratory viruses
are diagnosed: virus culture, serology, immunofluorescence/
antigen detection, and nucleic acid/PCR-based tests. Virus cul-
ture refers to the practice of infecting cell lines with clinically
obtained samples. Serology is where the blood is tested for
either virus-specific antibodies or viral antigen by a functional
assay. The disadvantage of both virus culture and serology is
that they are labor-intensive and slow to produce results. Tis-
sue cultures can take up to 10 days, and the antibody response
to a viral infection can take 2 weeks to develop. Therefore, the
infection can often be resolved before the infectious agent is
defined. These two methods are no longer routinely used di-
agnostically but may have a role in epidemiological studies and
when used to follow the course of an infection.
Antigen detection is based on the use of virus-specific mono-
clonal antibodies. There are a variety of diagnostic test kits
based on antigen detection that are used for the rapid identi-
fication of virus. These tests use nasopharyngeal aspirate,
nasopharyngeal wash, or nasal swab specimens as test material
and detect viral antigen by use of either a conjugated enzyme
or fluorescence. Antigen detection-based tests are still widely
prevalent but are being replaced with nucleic acid-based tests;
these tests have been reviewed in depth elsewhere (214). Nu-
cleic acid tests are now being multiplexed, allowing the rapid
detection of many viruses concurrently. Nucleic acid tests are
significantly more sensitive than the other methods described
above, and this may have an impact on which viruses are
detected by studies.
The relative importance of individual viral agents in early
life is open to debate. Certainly, RSV, RV, PIV, and influenza
virus are predominant in the published data. However, as
shown in Table 1, there are several factors limiting the ability
to draw a definitive conclusion about which virus is the most
common or important: differences in the way that data were
collected (PCR versus immunoassay) between and within stud-
ies and the impact of assay sensitivity (214); differences in
study design affecting age, recruitment criteria, and which vi-
ruses are studied; skewing of data historically, particularly the
ease of in vitro detection of RSV compared to that of RV;
changes following the wider introduction of reverse transcrip-
tion (RT)-PCR; PCR diagnosis of virus that may not neces-
sarily indicate that the virus is causing disease (353) (there is
some evidence of viral RNA detection in asymptomatic chil-
dren [335] and evidence of viral persistence [153]); and the
predominance of hospital-based studies, which are skewed to-
ward more severe illness.
The following broad conclusions can be drawn about viral
etiology and infant hospitalization due to respiratory infection
(Table 1). First, influenza virus, adenovirus, hMPV, PIV, RV,
and RSV can all cause bronchiolitis, necessitating hospitaliza-
tion. Second, of these viruses, RSV has most commonly been
reported to be the main cause of hospitalization due to bron-
chiolitis and increased disease severity, followed by RV and
then by influenza virus. Third, viral coinfection is relatively
common, occurring in about 20% of cases. However, there is
no consensus on the effect of coinfection on disease severity.
The effect may depend upon which viruses coinfect together.
For example, when adenovirus or rhinovirus was detected dur-
ing RSV infection, there was no increase in severity (3); how-
ever, coinfection with both hMPV and RSV increased the
intensive care unit admission rate (295). Finally, the profile of
viruses detected is changing due to the increasing use of nu-
cleic acid-based diagnostic screens and the discovery of newly
isolated viruses.
Knowledge of the infecting agent does not routinely alter
treatment except insofar as a positive viral identification will
reduce the inappropriate use of antibiotics and may allow the
cohorting of patients to reduce nosocomial infection. More
importantly, while knowledge of which virus is predominant is
relevant for the design of vaccines and specific prophylactic
treatments, what can be observed is the similarity of symptoms
caused by a wide range of viral agents. It may therefore be
more appropriate to focus on ways to target the symptoms and
not the agent. This may be especially relevant when an excess
immune response causes the disease or when there are multi-
ple serologically distinct subtypes circulating.
“New Respiratory Viruses”
Recently, several “new” viruses have been characterized, in
part triggered by new diagnostic technology, especially RT-
PCR. Recently isolated respiratory viral agents include human
metapneumovirus (hMPV) (337), found in samples from chil-
dren with RSV-like bronchiolitis who were RSV negative; hu-
man bocavirus (BoV), discovered by a random PCR screen of
respiratory tract samples (8); and two new polyomaviruses,
WU (106) and KI (9). Two questions arise about these new
viruses. First, are they truly new or only newly discovered? For
example, hMPV was shown to have been circulating for at least
50 years (337). Second, what is the clinical impact of these
viruses? hMPV certainly has clinical impact, and there is evi-
dence to suggest that BoV is pathogenic (46, 225), but data
from previously reported studies suggested that the new poly-
omaviruses are not pathogenic on their own (2, 244). The
discovery of new agents of infection is important because they
may play a role as coinfecting agents, altering disease severity.
Newly discovered viruses may also be important in future
outbreaks; for example, severe acute respiratory syndrome
(SARS) was caused by a coronavirus (103, 254), and corona-
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viruses had previously been considered to be minimally patho-
genic.
Who Gets Colds?
The likelihood of infection is determined by two factors: age
(234) and exposure to infection. The severity of infection once
it occurs is more complex and is determined by both environ-
mental and genetic risk factors. The risk factors for severe
RSV infection have been most thoroughly characterized (re-
viewed in reference 302), and they are as follows: (i) age when
infected (120); (ii) increased exposure to an infectious agent,
such as sibling order, day care attendance, birth season,
hospitalization, and socioeconomic status (245); (iii) de-
creased body size due to gestational age, malnutrition, and
birth weight; (iv) protection against virus due to breastfeed-
ing and the amount of IgG in breast milk; and (v) factors
affecting lung function, such as exposure to smoke and air
pollution.
Young age acts as a metafactor reflecting the interplay of
factors causing disease following viral infection (Fig. 1). Age
has an effect on the size of the child, particularly airway size,
transmission dynamics (due to multiple close contacts between
small children), and immune experience, all of which contrib-
ute to an increased severity of infection. Furthermore, younger
children have smaller energy reserves and are more likely to
get exhausted by the effort of breathing—the ultimate cause of
mortality in acute bronchiolitis. There are also critical differ-
ences in the infant immune system compared to that of adults
(discussed below) that directly affect infection.
Genetics
As well as environmental risk factors, genetic risk factors
have been identified. A large number of candidate gene asso-
ciation studies have been performed for both RSV (231) and
SARS-CoV, but studies have also been performed for influ-
enza virus and RV (Table 2). Significant correlations between
genes of the immune system and the risk of severe respiratory
viral infection have been observed. There is overlap among the
different viruses, with several of the same genes having an
association with disease, but this may reflect merely bias in the
selection of candidate genes. This in turn reflects the core
limitation of the candidate approach: it will answer only the
question posed rather than revealing novel interactions (305).
Candidate gene studies can be increased in power when sup-
ported by functional evidence of the effect of the polymor-
phism.
Two studies have taken a wider approach to look at the risk
of RSV bronchiolitis (150, 300). Of these studies, the earlier
study by Janssen et al. demonstrated that RSV susceptibility is
complex, but the strongest associations were with polymor-
phisms in the genes of the innate immune response (150). This
included the transcriptional regulator Jun, alpha interferon
(IFN-), nitric oxide synthase, and the vitamin D receptor. The
more recent study of preterm children by the same group also
indicated a critical association with innate immune system
genes and bronchiolitis susceptibility (300).
Another approach is to use animal models to either define
novel genes of interest or explore their function. There are
differences in the susceptibility of inbred mouse strains to
respiratory viral infection, which allow comparative studies.
Differences have been seen in mouse strain susceptibility to
RSV (122, 139, 265, 312). Alternatively, mouse models can be
used to support the findings of human studies. For example,
polymorphisms in surfactant protein A (SP-A) were associated
with an increased risk of RSV bronchiolitis (206), and SP-A-
deficient mice have an increased RSV viral load (194). The
role of Toll-like receptor 4 (TLR4) in RSV infection was also
clarified by a combination of mouse and human genetic stud-
ies. The initial importance of TLR4 was observed for mice
(179), and studies were then performed by using human airway
cells (233), leading to genetic studies of susceptibility (18, 143,
253, 269, 322).
There appear to be two loose groups of genes that are
important for altering the outcome following respiratory viral
infection. Genes in the first group are involved in the magni-
FIG. 1. Interplay of factors that cause disease following respiratory viral infection and impact of infancy. The ultimate cause of illness/disease
following respiratory viral infection is airway occlusion, which leads to a reduction in gaseous exchange, leading to respiratory distress. This airway
occlusion can be either immune or virally mediated and most probably is a combination of both. Early life has an effect on both virus- and
immune-mediated damage. The infant immune system is skewed to a hyporesponsive phenotype, with a reduced type I interferon response leading
to a higher viral load. The adaptive immune response is also skewed and limited in its effect. These factors act in combination with small body size
and small airways to further increase disease severity.
80 TREGONING AND SCHWARZE CLIN. MICROBIOL. REV.
 o
n
 June 19, 2013 by UNIVERSITY O
F EDINBURG
H
http://cm
r.asm
.org/
D
ow
nloaded from
 
TABLE 2. Genetic associations with respiratory viral infectiona
Group and gene Virus Effect of studied SNP Reference(s)
Inflammatory
mediators
CCL5 SARS-CoV 28G allele, which increases NF-B binding, increases the risk of fatality 239
IFN- RSV 453T allele (no known function) association on limited genome-wide approach 150
IFN- RSV Increased IFN- production associated with increased disease severity 108
SARS-CoV 874A allele, which reduces NF-B binding and increases SARS susceptibility 57
IL-4 RSV 589T allele, which increases transcription factor binding affinity, associated with
increased risk
56
RSV 589T allele study 130
RSV Study of 5q31 Th2 cytokine gene cluster 102
RSV No association with 589T SNP 271
IL-6 RV/RSV 174C allele, which decreases IL-6 expression, associated with increased risk of OM 11
RSV High-producing IL-6 alleles associated with shorter hospital stay 108
IL-8 RSV 251A allele, which increases IL-8 expression, associated with increased risk of bronchiolitis 136
251A allele, which increases IL-8 expression, associated with increased risk of wheeze 110
781C/T allele, which alters promoter binding, associated with asthma but not
RSV bronchiolitis
273
IL-9 RSV No association 129
IL-10 RV/RSV High-producing IL-10 allele associated with increased risk of OM 11
RSV 592C allele (no known function) associated with bronchiolitis 129
IV No effect on vaccine response 324
IL-13 RSV 1112T allele, which increases binding affinity, associated with increased risk of severe RSV
infection
271
Study of 5q31 Th2 cytokine gene cluster 102
Arg130Gln, which alters IL-13R1 binding, associated with increased risk of persistent
wheeze
92
IL-18 RSV 133G/C allele, which may alter STAT binding and IL-18 expression, associated with
increased RSV bronchiolitis
270
SARS-CoV 607T allele (no known function) associated with increased nasal shedding 54
TGF- RSV 509T allele, which increases TGF-1 expression, associated with RSV wheeze 131
TNF RSV No association 108, 129, 267
SARS-CoV 204C/T allele (no known function) associated with protective effect 345
PGI2 RSV No association 123
Receptors
CCR5 RSV 2459/G (decreases expression) and 2554/T alleles associated with severe RSV bronchiolitis 135
CD14 RSV 550C/T allele, which increases levels of soluble CD14, associated with risk of severe
RSV bronchiolitis
143
No association 269, 322
SARS-CoV 155C/C allele, which decreases level of soluble CD14, increases risk of SARS-CoV 356
CX3CR1 RSV Thr280Met (no known function) increases risk of RSV LRTI 14
E selectin RSV No association 178
FC	R1A RSV 66C allele (no known function) association on limited genome-wide approach 150
FCRIIA SARS-CoV Arg131His (no known function) associated with increased disease severity 357
HLA RSV No association 145
IV Increased frequency of HLA-DRB1*07 and decreased frequency of HLA-DQB1*0603-9/14
and DRB1*13 in nonresponders to IV subunit vaccine
107
SARS-CoV Association of HLA-B*4601 with severity of SARS infection 201
ICAM1 RSV No association 178
Continued on following page
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tude and type of the immune response but do not necessarily
control viral load. Alleles that lead to an increased level of
expression or efficacy of these genes increase the risk of severe
disease, for example, the interleukin-4 (IL-4) 589T allele
(56), the IL-8 251A allele (136), and the IL-13 1112T allele
(271). The second group contains genes that are involved in
the control of viral load. Alleles that lead to a decreased
expression of these antiviral genes increase the risk of severe
disease, for example, the TLR4 Asp299Gly polymorphism
(322), the CD14155C allele (143), and the IL-6174C allele
(11). This reflects the two arms that contribute to respiratory
viral disease damage caused by the virus and damage caused by
the immune system (Fig. 1).
VIROLOGY
Viral Detection by the Host
The initial detection of viruses by the immune system is
critical for their control and for shaping the response required
for clearing them. It is increasingly being recognized that there
are highly conserved host receptors that recognize basic com-
ponents of viruses, triggering an immune response. These viral
components, termed pathogen-associated molecular patterns
(PAMPs), are often constituents of the virus that cannot be
evolved away from, e.g., the physical makeup of their genomes.
Which pattern recognition receptors (PRRs) are involved in
the detection of respiratory viruses, particularly in vivo, has not
TABLE 2—Continued
Group and gene Virus Effect of studied SNP Reference(s)
ICAM3 SARS-CoV Asp143Gly (no known function) associated with decreased white blood cell counts 50
IL4RA RSV Gln551Arg, which may affect STAT6 binding; associated with increased RSV hospitalization 130
MBL RSV No association 175
SARS-CoV Low-expression polymorphisms associated with SARS infection 360
No association 357
Higher frequency of haplotypes associated with low or deficient serum levels of MBL in
patients with SARS than in control subjects
144
TLR4 RSV Asp299Gly and Thr399Ile, which reduce TLR4 translocation, associated with severe
RSV bronchiolitis
322
Asp259Gly increased risk of RSV infection 269
Asp299Gly and Thr399Ile were significantly overrepresented among infants with severe
RSV bronchiolitis
18
No association 143, 253
VCAM1 RSV No association 178
Vitamin D RSV FokI ff genotype, which reduces receptor expression associated with increased rates of ARI 281
receptor Thr1Met association on limited genome-wide approach 150
Others
FGL2 SARS-CoV Gly57Gln (no known function) associated with increased nasal shedding 54
JUN RSV 750G/A allele (no known function) association on limited genome-wide approach 150
L-Sign (CD209L) SARS-CoV No association 197
Homozygous expression of tandem repeats in CLEC4M may bind virus to cells and has a
protective advantage
51
MASP2 SARS-CoV No association 346
NOS2A RSV 2757A allele (no known function) association on limited genome-wide approach 150
SP-A RSV Gln223Lys, which may alter RSV binding, associated with severe RSV infection 206
SP-B RSV No association 268
SP-C RSV No association 272
SP-D RSV No association 177
Met11Thr, which may reduce opsonization, associated with increased risk of RSV
bronchiolitis
183
a The table shows genes that have been studied in association with an increased risk or severity of respiratory viral infection. Many of the studies were not specific
for infantile bronchiolitis, but due to the limited availability of published genetic study data, they have also been included here. Where known or speculated, the allele
and its putative function have been included. Abbreviations: SNP, single nucleotide polymorphisms; OM, otitis media; ARI, acute respiratory illness; URTI, upper
respiratory tract infection; LRTI, lower respiratory tract infection; TGF-, transforming growth factor ; MBL, mannose binding lectin.
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been clearly defined. This is reflected by the somewhat contra-
dictory nature of the data reported thus far. However, viral
detection and the upregulation of the type I interferon (IFN)
response are clearly important. The importance of this system
in acute viral respiratory infection of children is highlighted by
studies of the genome-wide association of RSV bronchiolitis,
which indicated a significant association between IFN- single
nucleotide polymorphisms (SNPs) and bronchiolitis (150, 300).
Furthermore, bronchial epithelial cells from asthmatics, who
are at an increased risk of severe viral infection, have been
shown to have deficient type I IFN (347) and type III IFN (66)
production. This increased susceptibility to infection may be
important for both the development and exacerbations of
asthma. As discussed below, infants have reduced type I IFN
responses (195), which may lead to increased disease severity
following viral infection.
The detection of viruses can occur extracellularly, in the
endosome, and in the cytoplasm (Fig. 2A). TLR2, TLR4, and
TLR6 are all extracellular receptors that have been character-
ized principally for the detection of bacterial products, both
lipopolysaccharides (LPSs) and lipoproteins. An increased
RSV viral load was observed for mice that were deficient for
TLR2 and TLR6 (236). RSV was shown to interact with TLR4,
normally associated with LPS, via its F protein (179, 236). On
some levels, this would seem counterintuitive since activating
TLR4 would induce an antiviral immune response, and viral
protein could evolve away from this. Indeed, it was suggested
that IL-12 and not TLR4 is important for viral control (85).
However, it may be that the interaction between TLR4 and
RSV is necessary for another viral function, for example, entry,
and the benefit of this outweighs the cost of activating the
downstream immune response, or the virus has evolved sec-
ondary mechanisms to inhibit the downstream response to
TLR4. An analogous situation may occur in SARS-CoV, which
was demonstrated to use the C-type lectins DC and L-Sign for
entry (121).
TLR3, TLR7, and TLR9 are located in the endosome and
have been demonstrated to be important for the detection of
virally associated genome components. TLR3 recognizes dou-
ble-stranded RNA (dsRNA), TLR7 recognizes single-stranded
RNA (ssRNA), and TLR9 recognizes unmethylated CpG re-
peats. The inhibition of TLR3 with small interfering RNA
(siRNA) impaired CCL5 and CXCL10 production following
RSV infection of human cell lines but did not alter viral load
(283). Anti-TLR3 treatment increased the viral load in human
cell lines following RV infection (126), and the use of a dom-
inant negative form of TLR3 blocked the NF-B response to
influenza virus in human cell lines (118). In vivo, TLR3/
mice have decreased inflammation and pathology but in-
creased influenza viral loads (187). Alpha interferon produc-
tion following influenza virus infection is reduced in murine
TLR7/ dendritic cells (DC) (81, 211). No association be-
tween RSV or RV and TLR7 has been observed; however,
other members of the family Picornaviridae have been shown
FIG. 2. Viral detection and viral evasion. (A) Viral detection by the innate immune system. Respiratory viruses are detected extracellularly by
TLR2, TLR4, and TLR6; in the endosome by TLR3, TLR7, and TLR9; and in the cytoplasm by RIG-I (retinoic acid-inducible gene I), MDA-5
(melanoma differentiation-associated gene 5), and NLRP3 (NLR family, pyrin domain-containing 3). (B) Viral evasion of the innate immune
system. Viruses inhibit the pattern recognition receptors RIG-I and MDA-5 and the downstream molecules IRF3, NF-B, and JAK/STAT. In some
cases the viral protein that inhibits the response has been identified. Abbreviations: AV, adenovirus; CoV, SARS coronavirus; hMPV, human
metapneumovirus; IV, influenza virus; PIV, parainfluenza virus, RSV, respiratory syncytial virus; RV, rhinovirus; TLR, Toll-like receptor; IFNAR,
interferon alpha receptor; ORF, open reading frame; CASP-1, caspase 1; NS, nonstructural.
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to interact with TLR7 in human cell lines (332). RSV infection
also increases the levels of TLR3 (115) and TLR4 (233) in
human primary airway cells and cell lines, which may sensitize
cells to future infection. TLR9 was observed to be important
for the detection of adenoviral vectors (16, 24, 49, 354).
The RIG-I-like receptor (RLR) family is a recently de-
scribed group of intracellular proteins that are able to detect
the viral genome in the cytoplasm. The prototypic member of
this family, RIG-I, was shown to be involved in the antiviral
response to influenza virus in mice (257) and to hMPV (198)
and RSV (204) in human cell lines. RIG-I mRNA levels pos-
itively correlate with RSV viral load in infected children (288).
Different members of the RLR family have different specific-
ities for viruses: MDA-5 was shown to be important for the
detection of the picornavirus encephalomyocarditis virus
(EMCV) in mice (161) but not influenza virus (188) or hMPV
(198) in human cell lines. The downstream adaptor protein for
the RIG-I-like family, IPS1/MAVS/CARDIF, was shown to be
critical for the detection of RSV using human cell lines (207,
249) and knockout mice (26).
There may be other methods of viral detection that are also
important, for example, the NOD-like receptor inflammasome,
which was recently demonstrated to be required for the im-
mune response to influenza virus (10, 141, 328), and -3 inte-
grins have been shown to be important for the detection of
adenovirus (83). Members of the C-type lectin family have
been associated with an increased severity of infection, includ-
ing surfactants (114) and mannose binding lectins (144, 278).
The protein DAI (DNA-dependent activator of IFN-regula-
tory factors; DLM-1/ZBP1) is a cytosolic DNA sensor and may
also be of importance for the detection of viruses (321), and it
is likely that there are other DNA receptors that are critical for
the detection of viruses.
Viral Evasion
The type I interferon (IFN) system is critical for the host
defense against virus, and evading it is of critical importance to
all viruses. All respiratory viruses have mechanisms to avoid
the type I IFN response (Fig. 2B). While structurally and
functionally diverse, the downstream result of these proteins is
to improve conditions for viral replication in host cells. The
host specificity of the virus is determined by its ability to evade
the type I IFN system, which was demonstrated for both influ-
enza virus (124) and RSV (36).
Viruses can hide their PAMPs; for example, the influenza
virus NS1 protein conceals the viral genome from detection
(200). RSV leader negative-strand RNA binds the La antigen,
which inhibits the RIG-I detection of RSV (27). Alternatively,
viral proteins actively subvert the function of pattern recogni-
tion receptors. Both influenza virus (257) and RSV (202) tar-
get RIG-I, and RV (22) targets MDA5. Downstream signaling
to these receptors can be inhibited. RSV was shown to inhibit
IFN production by plasmacytoid dendritic cells in response to
CpG (TLR9) and resiquimod (TLR7) (290). SARS-CoV was
shown to block NF-B function (170), and interferon response
factor 3 (IRF3) activation is inhibited by RV (174), RSV (309),
SARS-CoV (170), and PIV (210). Of interest is the increase in
NF-B function following RSV infection (309), and this may
contribute to the inhibition of apoptosis (28). Signaling from
the IFN- receptor by elements of the JAK-STAT pathway is
inhibited by RSV (274), hMPV (82), SARS-CoV (170), and
adenovirus (AV) (296).
The adaptive immune response is principally evaded by the
mutation of viral proteins. Most respiratory viruses (barring
adenovirus) have RNA genomes, and the combination of RNA
polymerase leakiness and a high level of viral turnover means
that there is a high rate of mutation (88). This is reflected in
the large number of circulating viruses (for example, there are
over 110 serologically distinct RVs) and results in multiple
infections by the same virus family within and between seasons.
The segmented genome of influenza virus further increases its
ability to rapidly change genotypes. The evolution of the influ-
enza virus genome is the driving factor behind the emergence
of pandemic strains, as observed for the recent H1N1 swine flu
pandemic (306). The coat proteins of viruses can also be al-
tered by changing glycosylation patterns (343). By altering the
glycosylation of H3N2 influenza virus, immune evasion in-
creased without altering infectivity (1). Reinfection with genet-
ically identical RSVs can also occur (294), suggesting that the
memory response that it induces may be poor.
Viruses also actively subvert the function of immune cells
that are directly infected. In vitro infection of DC with RSV or
hMPV reduces their antigen-presenting capacity, a change that
may be linked with the inhibition of type I IFN (116, 117).
However, other mechanisms may be utilized to suppress the
antigen-presenting capacity, thereby blinding the immune sys-
tem to the presence of virus. RV was demonstrated to induce
IL-10 in DC (315), influenza virus was shown to inhibit DC
function by both the hemagglutinin (HA) (243) and NS1 pro-
teins (97).
Persistence
There is also some evidence, mostly from models, that res-
piratory viruses are able to cause persistent infection. Persis-
tent and/or latent AV infection was demonstrated for children
with established bronchiolitis (213) but was not found in chil-
dren with chronic obstructive bronchitis (256). The persistence
of RV RNA was detected in the lungs of hospitalized children
(153). Persistence has also been demonstrated by using guinea
pig (125), bovine (334), and mouse models of RSV (293) and
hMPV (13, 205). However, the occurrence of persistent respi-
ratory viral infection, particularly the persistence of RNA vi-
ruses, is controversial. Furthermore, the role of persistent in-
fection and whether it is a function of the host or the virus are
unclear. Persistent infection may provide a pool of virus for
reinfection (173), or there may be a retention of a pool of viral
antigen and/or genomic material to maintain adaptive immune
memory (359).
In conclusion, viruses have evolved to evade the immune
system, and this immune evasion is critical for viral host spec-
ificity and has an important impact on the host response to
infection. The combination of viral immunosuppression and
the hyporesponsiveness of the early-life immune response may
increase the amount of virally mediated damage and therefore
increase disease.
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IMMUNOLOGY
Immunopathology versus Viral Pathology
A core question about respiratory viral infection is, how is
disease caused? This is focused around a central debate, the
relative impacts of virus and host on the pathogenesis of in-
fection, and has a critical bearing on approaches to limit the
effect of childhood infection. Unfortunately, it is very difficult
to separate the effects of one component from those of the
other. When the viral load is higher, disease is more severe, but
when the viral load is higher, the proinflammatory stimuli are
also greater, and therefore, the immune response is greater.
This subject has been thoroughly reviewed by Collins and Gra-
ham (63), so we will touch upon it briefly here.
Some evidence suggests that damage caused to the lung by
viral infection is the key factor. A recent study of the lungs of
infants who died of RSV infection demonstrated the presence
of virus but not lymphocytes (350). Of the nine children with
RSV disease analyzed in that study, two suffered from Down’s
syndrome and five had heart disease (in infants, presumably
congenital cardiac defects), both conditions which are often
associated with some degree of immunodeficiency. This sug-
gests that these findings may be particular to immunodeficient
or immunosuppressed individuals, for whom RSV infection is
known to be a major clinical problem, e.g., after bone marrow
transplantation (229). There is also a correlation between viral
load and disease severity in RSV (100) and hMPV (35) infections.
Direct viral damage was demonstrated for some viruses. RSV can
inhibit cilia movement, which might lead to airway blockade
(362). RV increases mucus production (23), and in vitro cytotox-
icity has been seen for RV infection (37). In fatal cases of SARS-
CoV, viral infection damages primarily type 1 and, to a lesser
extent, type 2 pneumocytes (240). Data from fatal influenza in-
fection are confounded by the regular occurrence of bacterial
coinfection (241), but inhibiting the cytokine response in a mouse
model had no effect on H5N1 pathogenesis (286), and IL-1
knockout mice had worse pathology for influenza virus (291, 319).
However, there is also plenty of evidence to support the idea
of immunopathology. An autopsy study of an RSV-infected
child who died in a vehicle crash demonstrated substantial
lymphocytosis (155). RSV-infected HIV-positive infants had
increased viral shedding but decreased bronchiolitis (52).
There are parallels between fatal SARS-CoV and H5N1 influ-
enza virus infections: lung infiltration by macrophages is asso-
ciated with disease (55). Data also demonstrate that the virus
had cleared from the lungs of patients who died of SARS or
fatal H5N1 infection (240, 333). Furthermore, in both SARS-
CoV and H5N1 infections, antiviral drugs were used on fatally
infected patients but did not alter disease outcome. Both RSV
and RV are characterized by neutrophilic infiltrate (227, 261).
The main neutrophil chemoattractant, IL-8 (CXCL8), was
shown to be upregulated in the airways of RSV bronchiolitics
(226) and asthmatic children during RV infection (327). For
RV, CD8 T cells are closely associated with fatal asthma ex-
acerbations (250). There is a requirement for synergistic stud-
ies of animals and humans, both of which give incomplete
answers but can contribute insight into the whole. Data from
animal studies mainly support the idea of immunopathology.
For example, the depletion of T cells during primary viral
infection of BALB/c mice inhibits disease (113). Until very
recently, there was no RV mouse model available, but the
recent development of such a model should allow complemen-
tary studies to be performed (23).
It is our view that immunopathology does play a role in
disease, and this needs to be taken into consideration in the
development of preventative treatments. However, there can
be a sliding scale of the relative contributions of viral pathology
and immunopathology where the end point of observable dis-
ease is the same.
Bacterial Coinfection
One interesting side effect of respiratory viral infection is
increased susceptibility to bacterial coinfection. This has been
reported for RSV (330) but is highly associated with influenza
virus infections (282). Many of the fatalities due to the 1918–
1919 flu pandemic were caused by secondary bacterial pneu-
monia (166). Viral infection enhances bacterial infection in
two ways, altering physical barriers and altering immune sys-
tem barriers. Viral infection (and the subsequent immune re-
sponse) may damage the lung epithelia, increasing bacterial
entry (263). The neuraminidase protein from influenza virus
plays an active role in thinning mucus and exposing receptors
on epithelial cells, leading to increased bacterial infectivity
(255). Viral infection can also skew the immune response,
allowing greater infection. Influenza infection can inhibit neu-
trophilia, leading to increased bacterial infection (61, 228).
Viral infection was proposed to increase the expression of host
receptors used by bacteria to enter cells, particularly platelet-
activating receptor, a key factor for Streptococcus pneumoniae
infection (338); however, other studies suggested that this is
not the case (224). Bacterial coinfection often happens in the
later stages of viral infection, during the dampening of the
immune response. IL-10 is a key cytokine in the resolution of
the immune response, but it can lead to increased bacterial
infection (339). A general downregulation of pathogen sensing
may also occur following viral infection, leading to an in-
creased incidence of bacterial infection (80). The incidence
and importance of subsequent bacterial coinfection have a
considerable impact on the prescription of antibiotics (209).
Infant Immunology
The infant immune system is different from the adult im-
mune system, and this has a critical impact on susceptibility to
respiratory viral infection. There is a general naivety of the
infant immune system: the lack of prior exposure to pathogens
leads to a lack of immune memory. However, there is also a
tendency toward hyporesponsive immune responses in early
life, characterized by both reduced innate and adaptive im-
mune responses (4). This is a critical adaptation to survive
early-life exposure to previously unseen nonpathogenic anti-
gens of both self and foreign origins. Infant immune responses
are also characterized as being T-helper 2 (Th2) skewed; this is
in part reflective of the immune response of the fetus. Preg-
nancy is strongly associated with Th2 cytokines, which is im-
portant for the avoidance of rejection (29). A Th1 environment
can be associated with preeclampsia, a complication of preg-
nancy (19); furthermore, infections that skew the environment
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toward Th1 during pregnancy (e.g., Chlamydophila abortus in
sheep) can cause abortions (91). This fetal Th2 skewing ex-
tends into early childhood and influences the immune re-
sponses to infection and possibly the development of asthma
and allergy. Immune responses in pregnancy can also be damp-
ened by other means, for example, an increased level of pro-
duction of L-arginase leading to a local depletion of L-arginine
and functional T-cell hyporesponsiveness (176). The removal
of the baby from the uterine environment removes this immu-
nosuppression, as observed by the similarity in neonatal im-
mune responses compared by birth rather than gestational age.
The innate immune response of infants is much reduced com-
pared to that of adults (195). Studies have demonstrated that
there are reduced responses to innate stimuli, including model
TLR ligands: LPS (196), poly(I:C) (79), and CpG oligonucleo-
tides (78). The level of the response may depend upon the effec-
tor molecule that is being used as a readout: the level of IL-6
appears to be increased (15), while the level of tumor necrosis
factor (TNF) (196) or type I IFNs (78, 79) is decreased. Interest-
ingly, it was demonstrated that the level of expression of Toll-like
receptors on cord blood dendritic cells is not different from that of
adults (196, 342). However, the level of expression of proteins
downstream of these receptors, including MyD88 (285), IRF3 (5),
and IRF7 (74), is decreased in cord blood-derived DC. It is
therefore possible that early-life innate responses are controlled
by the suppression of adaptor proteins. This suppression at the
“choke point” of signal transduction may be the most efficient way
of globally limiting the immune response.
The level of the adaptive immune response in infants is also
reduced. This may be a downstream consequence of the failure
to initiate type I IFN responses and therefore minimal DC
activation, but other mechanisms may be involved. Dendritic
cell immaturity, specifically the reduced level of production of
IL-12 (112), may lead to the reported skewing of the immune
response to a Th2 phenotype. In addition, both CD4 and CD8
functions were reported to be deficient, which may in turn lead
to reduced viral clearance and increased reinfection. B-cell and
antibody responses to infant vaccination are especially poor,
with weaker, shorter-lived responses (299). Although not fully
understood, the failure to produce high levels of antibody has
been linked to several aspects of the B-cell response. First,
infants have immature B cells affecting the strength of the
antibody response. Second, there is a failure of signaling for
the crucial B-cell survival factors BAFF (B-cell activating fac-
tor of the TNF family) and APRIL (a proliferation-inducing
ligand), with reduced levels of APRIL expression (25) and
reduced levels of expression of the receptors TACI (transmem-
brane activator and calcium modulator and cyclophilin ligand
interactor), BCMA, and BAFF-R (162) leading to the rapid
waning of the antibody response observed. These factors have
been identified as being determinants of the mucosal antibody
response to RSV infection (276). Finally, the immaturity of
dendritic cells in early life (112) might also influence the
strength of B-cell responses; for example, there is poor follic-
ular dendritic cell development in neonatal murine germinal
centers (259). Although reduced in magnitude, infants do de-
velop a memory response to infection, which reduces the effect
of subsequent infections with the same virus.
The early-life immune response may also be actively sup-
pressed. CD25
 CD4
 regulatory T cells (Tregs) were shown
to inhibit the murine neonatal immune response to herpes
simplex virus (96). Children born to mothers with placental
Plasmodium falciparum infection are more susceptible to ma-
laria (189), and this may be associated with the enhanced
development of P. falciparum-specific Tregs in cord blood
(39). B cells may play a role in the suppression of infant
immune responses; a subset of B cells, CD5
 (B1a) B cells,
was shown to be suppressive (318, 363).
Asthma
Another aspect of pediatric respiratory viral infection linked
to the immune system is the development of asthma following
viral bronchiolitis. Whether viral bronchiolitis is causative of
wheezing or is indicative of a child prone to wheezing is un-
clear (260). The ultimate cause of asthma is likely to very
heterogeneous, reflective of the heterogeneity of asthma itself,
with contributions from the environment, infection, and the
child’s genotype (220). There is a strong connection between
infant viral bronchiolitis and wheezing in later childhood (260).
Links between infant infection with hMPV (105), RV (147,
192), and RSV (99, 301, 313) and later-life wheezing have been
demonstrated. Blocking viral infection with drugs (53) or a
prophylactic antibody (303) may reduce the incidence of
asthma and wheeze in later life. However, other studies have
shown that early-life viral infection is protective against asthma
(142), and a recent study suggested that hospitalization with
viral bronchiolitis does not cause asthma but may be an indi-
cator of a genetic predisposition to asthma (329).
If viral infection is causative, what is the mechanism? The
cytokine balance of the infant lung may have an impact on
the development of asthma, and early-life respiratory viral
infection may alter this (212, 221). Data from genetic studies
(see above) suggested links between several cytokine genes
and RSV severity (305). Again, animal models may contrib-
ute to our greater understanding of this issue. When neo-
natal BALB/c mice are infected with RSV, it predisposes them
to more severe disease upon reinfection as adults (71), and this
is linked to T cells (331), IL-13 (73), and IgE (72).
Viral infection was shown to be an important cause of acute
exacerbations of wheezing (7, 154, 157). This enhanced allergic
airway disease can also be observed following influenza virus
(219), RSV (21), and RV (23) infections in mouse models. The
mechanistic links between viral infections and asthma, how-
ever, are not well understood. While the immune response to
viral infection is characterized as T-helper 1 (Th1) biased,
allergic asthma is characterized as T-helper 2 (Th2) biased.
Earlier work focused on the inflammatory infiltrate in asthma,
but the airway epithelium is now appreciated to have a role in
triggering and orchestrating the immune response (132). One
epithelial product of particular interest is thymic stromal lym-
phopoietin (TSLP), an interleukin-7-like cytokine identified as
being a murine B-cell-line growth factor (304). TSLP was de-
scribed as having a role in the development and pathology of
allergic asthma. Patients with asthma have higher levels of
TSLP (355), and TSLP was demonstrated to be critical in
mouse models of allergic airway disease (12, 365). Its probable
role in asthma is to act as a Th2 amplification factor, inducing
dendritic cells (DCs) to differentiate CD4 T cells to a Th2
phenotype (308) via OX40L (146) and activating mast cells (6).
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The expression of TSLP has been observed following RSV
infection (344) and RV infection (160), but it is not known how
this occurs and what effect this has on subsequent allergic
responses. The expression of TSLP is induced by TLR2 (185)
and TLR3 (160) ligation via the NF-B complex. This induc-
tion is potentiated by a Th2 environment (160, 164). The pat-
tern recognition receptors (PRRs) that lead to TSLP induction
are also associated with viral detection; for example, RSV can
be detected by both TLR2 (236) and TLR3 (284). The
possibility therefore arises that viral infection of epithelial
cells in the context of a Th2-skewed background induces
TSLP, leading to the amplification of the Th2-skewed re-
sponse. This might have a role both in exacerbations of
asthma and in the development of asthma in the context of
neonatal Th2 skewing (4).
Challenges: Back to the Bedside
How should infant infection be controlled? In part, this
depends upon the conclusions drawn from the immunopathol-
ogy-versus-viral-pathology arguments. If viral pathology is the
critical aspect, then specific, preventative treatments including
vaccines and antiviral drugs are more appropriate. If, however,
immunopathology is foremost, then methods to limit the im-
mune system and careful assessment of vaccines for immuno-
pathology are required.
What hope is there for a vaccine? There is an influenza virus
vaccine, and this is now routinely administered to all children in
the United States from 6 months to 18 years of age annually (64).
This has been demonstrated to reduce the rate of influenza in-
fection (264). The prevalence of influenza may lead to its routine
use in other countries, especially in the aftermath of the pandemic
H1N1 outbreak. An additional benefit of widespread immuniza-
tion programs might be reduced viral carriage and therefore pro-
tection of nonimmunized groups as observed for Haemophilus
influenzae type b (Hib) (162a). However, the mutation rate of
influenza virus and the significant animal reservoir mean that
there is a need for an annual vaccination program, and therefore,
the cost of this may reduce the wider introduction of the vaccine.
For other viruses, there are a number of roadblocks to the
development of a vaccine. There are the general challenges
posed by the development of any new vaccine, both societal
and scientific. These challenges are compounded by specific
problems associated with pediatric vaccination caused by the
limitations of the infant immune system (298). There are also
virus-specific challenges; for example, with RSV, there is the
specter of the formalin-inactivated RSV (FI-RSV) trial in the
1960s (163). Viral mutation rates may make conventional B-
cell-based vaccines against respiratory viruses virtually impos-
sible to create. One approach might be to focus upon T-cell
epitopes, which were shown to be cross-reactive in RV (109).
However, we might speculate that the use of T-cell-based vac-
cines may have drawbacks with regard to immunopathology;
for example, RSV vaccines based on T-cell epitopes alone
caused enhanced disease pathology (248). An alternative ap-
proach might be to vaccinate pregnant mothers and thus pro-
vide protection during the first few months of life (358), when
the infant is most vulnerable, but to allow normal infection to
take place after that.
What role could antiviral drugs play? There are some
antiviral agents available: ribavirin for RSV and oseltamivir
and zanamivir for influenza virus. There are also several new
drugs in development, some of which have reached phase II
clinical trials. These include ALN-RSV01 (Alnylam), an
RNA interference (RNAi)-based drug; RSV-604 (Arrow/
Novartis, United Kingdom), an N protein inhibitor of RSV
(246); and plecoranil (Schering-Plough), an RV VP1 inhibitor
(280). A particular problem with antivirals is that they are
prone to inducing viral escape mutants, particularly for the
highly plastic RNA viruses; for example, escape mutants asso-
ciated with oseltamivir require only a single point mutation
(76). A further problem with antiviral drugs is the timing of
application; for example, anti-influenza virus drugs need to be
applied during the first 48 h of illness to be effective.
Debate arises over the cost-effectiveness of preventative
treatment. Vaccines represent the best cost-effectiveness, but
apart from influenza virus vaccines, this option is not available.
The alternative, passive immunization, e.g., with the monoclo-
nal antibody palivizumab, is expensive; current costs in the
United Kingdom are about £1,800 (US$3,600) per season for
an infant of 3 to 4 kg of body weight: 5 monthly injections at 15
mg per kg, i.e., about a vial per month (based on 2008 figures)
(158). Furthermore, anti-RSV antibody escape mutants have
been isolated (364), and studies indicated that this treatment is
cost-effective only for the highest-risk infants (89, 90). An
improved antibody to replace palivizumab with increased af-
finity for the RSV F protein (motavizumab) has been tested in
phase III clinical trials but has not yet been licensed at the time
of writing.
Are there any alternative approaches? Potentially, toe use of
anti-inflammatory drugs and treatments might be effective,
especially if disease following respiratory infection is immune
mediated. This is particularly attractive in light of the reemer-
gence of the concept of hypercytokinemia, or the “cytokine
storm.” This term was coined in 1993 to describe graft-verses-
host disease (98). The term refers to systemic inflammatory
disease caused by an excess of proinflammatory cytokines, in
particular TNF. It has been associated with fatal cases of H5N1
influenza virus (75) and SARS-CoV (134) infection.
The advantage of a general anti-inflammatory approach is
that it is not limited to a specific virus. However, opinion is
mixed as to whether this would be effective. There is evidence
for success in animal models. Broad-range anti-inflammatory
treatments have been shown to reduce disease severity of in-
fluenza infection: gabexate (a synthetic protease inhibitor,
which inhibits cytokines) reduced inflammation but did not
alter survival (172), and gemfibrozil (another broad-range cy-
tokine inhibitor) increased rates of survival for mice infected
with influenza from 26% to 52% (41). However, the use of
glucocorticoids has not been demonstrated to have any effect
on RSV bronchiolitis (93, 252), although their anti-inflamma-
tory effect may be too slowly mediated for a viral infection.
Specific treatments against proinflammatory mediators can
have significant effects on reducing disease in animal models.
Blocking or depleting of cytokines including TNF (140, 319),
IL-4 (65), IL-13 (156), and IL-12 (326); chemokines, including
CCL11 (eotaxin) (223), CCL5 (RANTES) (70), and the recep-
tor CCR1 (230); and costimulatory markers, including ICOS
(137) and OX40L (138) has been shown to be effective in
reducing disease. However, other studies have shown that the
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inhibition of some mediators either has no effect or worsens
disease, including IL-1 (286, 319), TNF (238), and CCL2
(monocyte chemoattractant protein 1 [MCP-1]) (77).
One issue with treatments that dampen the immune re-
sponse is their nonspecific effect; for example, long-term
anti-TNF treatment has been shown to lead to tuberculosis
reactivation. Another issue is timing; immunity-dampening
treatments during the early phase of infection might in-
crease viral load and, therefore, virally induced damage.
Ultimately, the most effective treatment might be treatment
based on a combination of antiviral drugs used early in the
disease course and anti-immunity drugs later on.
CONCLUSION
An important consideration in the development of control
measures against respiratory viral infection, in particular vac-
cines, is early-life immunity development. The early-life im-
mune system appears to be suppressed; how this suppression is
relaxed over time and the role of infection in the development
of normal immune responses are of critical importance.
Infection/colonization with normal flora may be necessary in
shaping normal immune responses. If this is the case, it has
important implications for vaccination strategies: increases
in vaccination coverage which reduce viral infection in early-
life might have an impact on immunity development, leading
to more severe infection/asthma in later life (111).
Another important consideration is a seeming paradox:
given the hypothesis that disease following respiratory viral
infection is immune mediated and infant immune responses
are dampened, why do infants get more severe infections (Fig.
3)? The first possibility is that all damage and disease are
mediated directly by the virus, with no immune component.
This higher viral load may be exacerbated by the lack of pre-
vious exposure and therefore the lack of protection against the
infectious agent. However, as argued above, there is significant
evidence that suggests that the immune system does play a role
in disease following viral infection. It may be that because the
response to pathogens is diminished, infection is more aggres-
sive, leading to a higher viral load prior to the initiation of the
FIG. 3. The paradox of early-childhood immune hyporesponsiveness and virally induced immunopathology. Shown are possible mechanisms by
which increased immunopathology may occur in the context of dampened responses to infection in infants. Similar levels of pattern recognition
receptors are detectable for infant and adult leukocytes. However, the molecules that transduce the signal, e.g., IRF3 and IRF7, have reduced
function. This leads to an altered immune response, with higher viral load, decreased immunoregulation (via IDO [indoleamine 2,3-dioxygenase]),
and skewed cytokine production, all of which may increase damage caused by the immune response. Abbreviations: PRR, pattern recognition
receptor; IRF, interferon response factor.
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immune response, and thus, the resulting response is greater in
magnitude and causes more collateral damage.
Alternatively, there may be a reduced regulation of the im-
mune response in infants, leading to increased immunopathol-
ogy. An engagement of the type I IFN response may be nec-
essary for a controlled immune response that is sufficient to
clear infection without much bystander damage (84). The ex-
pression of the immunoregulatory enzyme indoleamine-2,3-
dioxygenase (IDO) was demonstrated to be upregulated by
both type I (IFN-/) and type II (IFN-) interferons (266).
Another regulatory molecule (nitric oxide) was shown to be
induced by Th1 but not Th2 T cells (325) and may be absent in
infants. Therefore, reduced signaling through the normal type
I IFN pathway during infection in early infancy may lead to a
more pathogenic immune response. Finally, cord blood-de-
rived dendritic cells were shown to have a bias toward IL-23
production (336); this cytokine is associated with an increased
development of proinflammatory Th17 T cells. All these fac-
tors may lead to a pathogenic rather than protective immune
response.
In conclusion, respiratory viral infection is an important
cause of morbidity and mortality in early life (Table 3). The
disease that is seen in children is composed of both a virus- and
an immune-mediated component. The relative contributions
of these two factors vary among individuals and are influenced
by the infecting virus, host genetics, and age. That there is an
immune component is important in considerations regarding
the development of vaccines and antiviral treatments.
Outstanding Questions
Outstanding questions in this field of research include the
following. (i) What drives viral lung disease: virus-induced
damage or the immune system? (ii) Does viral infection cause
wheezing in later life, or is it an early marker of a wheezy child?
(iii) What is the most appropriate way to control viral infec-
tion, and does it even need to be controlled? (iv) If disease
following respiratory viral infection is indeed immune medi-
ated, how do the immature immune responses in early child-
hood contribute to the development of severe LRTI?
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ADDENDUM
While the manuscript was in preparation, a novel influenza
virus H1N1 strain emerged (A/California/7/2009). On 11 June
2009, the WHO raised the pandemic alert level to 6, signifying
the first influenza pandemic since 1968. As of 18 September
2009, the WHO estimated over 296,471 cases of H1N1 infec-
tion (with the caveat that “countries are no longer required to
test and report individual cases; the number of cases reported
actually understates the real number of cases”) and at least
3,486 fatalities. The U.S. Centers for Disease Control and
Prevention (CDC) reported that the rates are similar to or
lower than those for seasonal influenza and that the number of
deaths is within the bounds of what is expected for this time of
year, with 9,079 cases and 593 deaths (dated 4 Sept 2009). The
Health Protection Agency in the United Kingdom reported
13,471 cases and 78 deaths (dated 17 September 2009). The
influenza pandemic does not appear at this point to be any
more skewed toward the pediatric population than seasonal
influenza, although there may be an increased severity in preg-
nancy. Two recent studies of hospitalized children from the
United Kingdom indicated that a large proportion of the chil-
dren had preexisting disorders (31 out of 77 cases [119] and 32
out of 58 cases [203]; in the latter study, 9 out of 58 cases died,
all of which had preexisting disorders).
The situation is changing rapidly, and therefore, anything
written here, although accurate at the time of writing, may be
incorrect by the time of publication. This pandemic does raise
important points of note, particularly about the socioeconomic
effect of respiratory infections. One important observation is
about the use of antiviral drugs. Specifically, oseltamivir use
has greatly increased and has moved from a preventative con-
TABLE 3. Comparative features of respiratory viral infections during infancya
Parameter
Virus
RSV RV Influenza virus
Estimated occurrence rate 688/1,000 (infected 1st yr),
826/1,000 (infected 2nd yr)
0.51/child/mo 5-30% outpatients, 0.1% inpatients
Seasonality Winter (October–March) Fall and Spring Epidemics
Effect of glucocorticoids None observed Possible reduction in wheeze None observed
Severity Can cause bronchiolitis
requiring hospitalization
Can cause bronchiolitis
requiring hospitalization
Can cause bronchiolitis requiring hospitalization
Control Specific antibody (palivizumab) Nothing currently Seasonal vaccine
Antiviral drug (ribavirin) Antiviral drugs (oseltamivir and zanamivir)
Genetic risk factors Antiviral genes reduce severity Limited studies but suggestion Limited studies
Immune response genes that cytokine genes are
increase severity important
Host viral detection RIG-I, TLR3, TLR4 TLR3 RIG-I, TLR3, TLR7, NLRP3, Casp-1
Viral host evasion Inhibits RIG-I, IRF-3, STAT Inhibits MDA5, IRF-3 Inhibits RIG-I
Immunopathology Strong association Evidence of role of IL-8 Cytokine storm
Asthma Associated with later-life
wheeze and exacerbations
Associated with later-life
wheeze and exacerbations
Associated with exacerbations
a The table compares the 3 most common viruses occurring in infants and summarizes various aspects described in detail in this review.
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trol medicine prescribed to those in contact with individuals
with confirmed influenza virus infection to being prescribed to
anyone with suspected influenza. A second point is the use of
vaccines; a vaccine has been developed, but the production of
this vaccine may reduce the capacity to produce the annual
seasonal influenza virus vaccine. The distribution of both vac-
cines and antiviral drugs has been skewed toward richer coun-
tries (62). Another concern is the impact on what is already
seen as a fragile economic recovery, by affecting consumer
confidence and spending. It will be of great interest to see how
this pandemic plays out and what effect it has on strategic
health care planning for the future.
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